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Background:  Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control, body weight, and blood 
pressure in patients with type 2 diabetes mellitus (T2DM). It also increases high-density lipoprotein cholesterol (HDL-C) and low-density 
lipoprotein cholesterol (LDL-C) levels, with no change in the LDL-C:HDL-C ratio. The beneficial effects of CANA may lead to improvements 
in insulin resistance, which is present in T2DM. Here we evaluate the effects of CANA on triglyceride (TG):HDL-C ratio, a marker of insulin 
resistance.
methods:  Data were pooled from four 26-week, Phase 3 clinical studies that evaluated efficacy and safety of CANA versus placebo (N = 
2,313). The effect of CANA on TG, HDL-C, and TG:HDL-C ratio was evaluated.
results:  Placebo-subtracted least squares mean percentage change from baseline (95% confidence interval) with CANA 100 mg and 
300 mg was −5.2% (−10.0, −0.3) and −7.6% (−12.5, −2.8) for TG, and 5.4% (3.6, 7.2) and 6.3% (4.5, 8.2) for HDL-C, respectively. CANA 
improved (i.e. decreased) the TG:HDL-C ratio; placebo-subtracted least squares mean percentage change from baseline (95% confidence 
interval) was −10.0% (−15.5, −4.4) with CANA 100 mg and −12.3% (−17.9, −6.8) with CANA 300 mg. Of the patients with an elevated 
TG:HDL-C ratio (≥ 3.5) at baseline and with a post-baseline assessment (n = 1,031), a larger proportion of patients treated with CANA 100 
mg (108 of 375; 28.8%) and 300 mg (122 of 361; 33.8%) had a normalized TG:HDL-C ratio (< 3.5) after 26 weeks versus placebo-treated 
patients (62 of 295; 21.0%). Differences in proportions (95% confidence interval) were 7.8% (1.0, 14.6) and 12.8% (5.7, 19.8) for CANA 
100 mg and 300 mg versus placebo, respectively.
conclusion:  Treatment with CANA for 26 weeks resulted in significant improvements in TG and HDL-C levels, and TG:HDL-C ratio. 
Among those with a TG:HDL-C ratio ≥ 3.5, a higher proportion of patients treated with CANA normalized TG:HDL-C to < 3.5 versus 
placebo, suggesting that in addition to improving glycemic control, body weight, and blood pressure, CANA may also improve insulin 
resistance. Collectively, these changes could have a positive impact on cardiometabolic risk in patients with T2DM.
